drugset / Trial / NCT02401022

The Study of AZD8529 for Smoking Cessation in Female Smokers

NCT02401022

Phase 2 Completed 214 enrolled National Institute on Drug Abuse (NIDA)
RandomizedParallel-groupTriple-blindTreatment

Summary

To evaluate the efficacy and safety of AZD8529 for smoking cessation in female smokers.

Timeline

Start
2015-07
Primary completion
2016-11
Completion
2017-01

Drugs

EvaluationDrugModalityDoseRoute
Comparator AZD8529 Other / unclassified 1.5 mg
Comparator AZD8529 Other / unclassified 40 mg

Indications